

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Kim et al.

Application No. 10/500,696

Filed: July 1, 2004

Confirmation No. 3101

For: NOVEL ANTI-VIRAL VSF PROTEIN AND
HYBRIDOMA PRODUCING THE SAME

Examiner: Benjamin P. Blumel

Art Unit: 1648

Attorney Reference No. 7037-69151-01

**FILED VIA EFS
ON OCTOBER 5, 2007**

SUBMITTED VIA ELECTRONIC FILING SYSTEM
COMMISSIONER FOR PATENTS

INFORMATION DISCLOSURE STATEMENT PURSUANT TO
37 C.F.R. § 1.97(c)

Listed on the accompanying form PTO-1449 and enclosed herewith is an English-language document. Applicants respectfully request that this document be listed as a reference cited on the issued patent. This Information Disclosure Statement ("IDS") is being mailed before Applicants received a final action, a notice of allowance, or an action that otherwise closes prosecution in the referenced application.

Submitted herewith via EFS is a payment of \$180.00 as required by 37 C.F.R. § 1.17(p) for filing this IDS in compliance with 1.97(c).

Please charge any additional fees which may be required in connection with filing this IDS, or credit any overpayment, to Deposit Account No. 02-4550.


The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 595-5300
Facsimile: (503) 595-5301

By


Sheree Lynn Rybak, Ph.D.
Registration No. 47,913